NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Now, if the current slide indicates "over 90%" (for the first time, I believe), then this would be at least 298 patients.
Thus, an increase of at least 12 patients that have crossed between the Spring 2017 refresh, and the currently reflected data ... supposedly current through November 2018.

Well, the photo from the conference I looked at shows > 90%

Thus the control arm was at least 12% progression free in the '17 dataset, and presumably more like 15-20% as not all would have progressed and crossed in that timeframe.

Possible, yes. Question is, does that imply the control arm was doing well even before cross-over? And what does that imply?

BTW, Pyrr's "do not see it" should be fairly obvious. He is asserting the trial has already failed the inter-arm comparison and thus NWBO is spinning it as a single arm trial.